Evaluation of prescribing pattern of vancomycin at the Payambar-e-Azam Hospital of Bandar Abbas

Document Type : Research Paper

Authors

Infectious and Tropical Disease Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

Abstract

Abstract
Introduction: Due to the significant use of vancomycin antibiotic in hospitals and the need for rational use of this antibiotic to prevent the occurrence of antibiotic resistance, the present study was conducted to evaluate the administration and pattern of vancomycin antibiotic use in the Payambar-e-Azam Hospital of Bandar Abbas.
Materials and Methods: The present study was a retrospective descriptive study in the 2017 year. Patients treated with vancomycin during one year were selected by reviewing the information of patients admitted to the Payambar-e-Azam Hospital of Bandar Abbas. Then, referring to the records of these patients in hospital medical records, the required information was extracted. The information was then reviewed by an infectious disease specialist according to the Infectious Diseases Society of America (IDSA) and Defined Daily Dose (DDD) guidelines.
Results: In this study, 189 patients receiving vancomycin antibiotics in different wards of the Payambar-e-Azam Hospital of Bandar Abbas were evaluated. Of the patients studied, 49 (26%) received vancomycin in the first line of treatment. 170 (90%) were prescribed antibiotics based on experience and 19 (10%) on antibiogram testing. Among the recipients of vancomycin antibiotics, antibiotic use for 92(48/7%) patients was based on a defined daily dose (DDD).
Conclusion: In the present study, about half of the prescribed vancomycin was administered according to DDD guidelines, but most of the treatments are experimental without regard to antibiogram and culture results.

Keywords


1. Holloway K, Green T, Carandang E, Hogerzeil H, Laing R, Lee D. Drug and therapeutics committees A
practical guide. World Health Organization. https://apps.who.int/medicinedocs/en/d/Js4882e/ (2003).
2. Bamigboye BT, Olowe OA, Taiwo SS. Phenotypic and molecular identification of vancomycin resistance in
clinical Staphylococcus aureus isolates in Osogbo, Nigeria. Eur J Microbiol Immunol 2018; 8: 25-30
3. Périchon B, Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents
Chemother. 2009; 53: 4580-7.
4. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and
development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet
Infect Dis. 2018; 18: 318-27.
5. European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe –
Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017. Stockholm:
ECDC; 2018.
6. Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, et al. Society for Healthcare
Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of
Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis
1997; 25: 584-99
7. Navarro R. Drug Utilization Review Strategies. In Managed Care Pharmacy Practice 2008, 215-229.
8. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, et al. Vancomycin
therapeutic guidelines: a summary of consensus recommendations from the infectious diseases society of
america, the american society of health-system pharmacists, and the society of infectious diseases pharmacists.
Clin Infect Dis 2009; 49: 325-7
9. Pharmaceutical Trends Overview Report. http://www.pmprb-cepmb.gc.ca/CMFiles/PTOR_June_0638MBI6232006-5829.pdf. 2006
10. Mousavi S, Behi M, Taghavi MR, Ahmadvand A, Ziaie S, Moradib M. Drug utilization evaluation of
imipenem and intravenous ciprofloxacin in a teaching hospital. Iran J Pharm Res 2013; 12: 161-7.
11. Nateghian AR, Robinson JL, Samadi B, Abdi N. Appropriate use of vancomycin in an educational tertiary care
hospital in Tehran, Iran. Med J Islam Repub Iran 2007; 21: 43-9.
12. Floret N, Thouverez M, Talon D, Thalamy B, Estavoyer JM. Evaluation of vancomycin use in a large
university‚Äź affiliated hospital in eastern France in 1999. Pharm World Sci 2001; 23: 93-7.
13. Vazin A, Japoni A, Shahbazi S, Davarpanah MA. Vancomycin utilization evaluation at hematology-oncology
ward of a teaching hospital in Iran. Iran J Pharm Res 2012; 11: 163-70
14. Raveh D, Muallem-zilcha E, Greenberg A, Wiener-well Y, Schlesinger Y, Yinnon AM. Prospective drug
utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and
meropenem. Q J Med 2006; 99: 397-406.
15. Carlier M, Carrette S, Roberts JA, Stove V, Verstraete A, Hoste E, et al. Meropenem and
piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect
pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 2013; 17:
R84.
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. In:
CLSI document M100S, 26th edn, Wayne: Clinical and Laboratory Standards Institute. 2016